ScoreWhy is ERIS Lifesciences Ltd ?
1
High Management Efficiency with a high ROCE of 16.70%
2
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 2.24 times
3
Poor long term growth as Operating profit has grown by an annual rate 17.18% of over the last 5 years
4
Positive results in Mar 26
- OPERATING PROFIT TO INTEREST(Q) Highest at 6.00 times
- PBT LESS OI(Q) At Rs 157.18 cr has Grown at 29.99%
- PAT(Q) Highest at Rs 281.61 cr.
5
With ROCE of 14.2, it has a Expensive valuation with a 4.2 Enterprise value to Capital Employed
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -0.24%, its profits have risen by 34.9% ; the PEG ratio of the company is 1.4
6
High Institutional Holdings at 26.75%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to ERIS Lifescience should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is ERIS Lifescience for you?
Medium Risk, Medium Return
Absolute
Risk Adjusted
Volatility
ERIS Lifescience
-0.24%
-0.01
29.97%
Sensex
-7.23%
-0.56
13.01%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
21.09%
EBIT Growth (5y)
17.18%
EBIT to Interest (avg)
32.22
Debt to EBITDA (avg)
1.59
Net Debt to Equity (avg)
0.75
Sales to Capital Employed (avg)
0.58
Tax Ratio
22.57%
Dividend Payout Ratio
0.28%
Pledged Shares
16.92%
Institutional Holding
26.75%
ROCE (avg)
17.25%
ROE (avg)
16.76%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
46
Industry P/E
35
Price to Book Value
6.66
EV to EBIT
28.20
EV to EBITDA
20.83
EV to Capital Employed
4.23
EV to Sales
7.44
PEG Ratio
1.42
Dividend Yield
NA
ROCE (Latest)
14.24%
ROE (Latest)
13.45%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend17What is working for the Company
OPERATING PROFIT TO INTEREST(Q)
Highest at 6.00 times
PBT LESS OI(Q)
At Rs 157.18 cr has Grown at 29.99%
PAT(Q)
Highest at Rs 281.61 cr.
EPS(Q)
Highest at Rs 20.33
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for ERIS Lifescience
Profit After Tax (PAT) - Quarterly
At Rs 281.61 cr has Grown at 200.1%
Year on Year (YoY)MOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Operating Profit to Interest - Quarterly
Highest at 6.00 times
in the last five quartersMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 157.18 cr has Grown at 29.99%
Year on Year (YoY)MOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 281.61 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 20.33
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
